Loading news...
CENTRAL TRUST Co boosted its stake in shares of Cencora, Inc. (NYSE: COR) by 116.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,500 shares of the company's stock after buying an additional 1,880 shares during the quarter. CENTRAL TRUST Co's holdings
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Se.
Atria Investments Inc lessened its position in shares of Cencora, Inc. (NYSE: COR) by 7.0% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,761 shares of the company's stock after selling 3,693 shares during the period. Atria Investments Inc's holdings in
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February.
BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of Cencora, Inc. (NYSE: COR) by 17.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 144,287 shares of the company's stock after purchasing an additional 21,933 shares during the period. BI
Adjusted Diluted EPS: $4.08, an increase of 9%.Consolidated Revenue: $85.9 billion, up 5.5%.Consolidated Gross Profit: $3.0 billion, up 18%.Gross Profit Margin
Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript
COR shares slip despite Q1 EPS beat and revenues match estimates, margins expand and fiscal 2026 growth guidance up.
Cencora reported higher Q1 earnings but missed revenue estimates, driven by U.S. and European drug sales growth.
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cencora (COR) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $4.07 per share. This compares to earnings of $3.73 per share a year ago.
Cencora on Wednesday beat Wall Street estimates for first-quarter profit, as the drug distributor rode the wave of sustained demand for specialty medicines and GLP-1 therapies.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,.
Mediolanum International Funds Ltd lifted its position in Cencora, Inc. (NYSE: COR) by 133.0% in the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 56,293 shares of the company's stock after acquiring an additional 32,138 shares during the period. Mediolanum International Funds Ltd's holdings in
Mawer Investment Management Ltd. lessened its position in Cencora, Inc. (NYSE: COR) by 3.1% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 650,671 shares of the company's stock after selling 20,938 shares during the quarter. Cencora accounts for 1.1% of Mawer
Thrivent Financial for Lutherans lowered its holdings in Cencora, Inc. (NYSE: COR) by 3.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 245,240 shares of the company's stock after selling 8,642 shares during the quarter. Thrivent Financial for Lutherans owned 0.13% of
Strategy Asset Managers LLC lifted its stake in Cencora, Inc. (NYSE: COR) by 133.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,814 shares of the company's stock after purchasing an additional 2,183 shares during the period.
Besides Wall Street's top-and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Bank of New York Mellon Corp lifted its stake in Cencora, Inc. (NYSE: COR) by 1.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,087,424 shares of the company's stock after buying an additional 16,076 shares during the quarter. Bank of New York Mellon
COR's Q1 outlook is supported by specialty utilization, RCA momentum, and steady international growth, even as GLP-1 tailwinds ease.